Finch Therapeutics Group (FNCH) Competitors $12.75 0.00 (0.00%) As of 07/14/2025 03:53 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock FNCH vs. FBRX, ENTX, TCRX, IGMS, VRCA, CABA, EPIX, ZURA, IPA, and QNCXShould you be buying Finch Therapeutics Group stock or one of its competitors? The main competitors of Finch Therapeutics Group include Forte Biosciences (FBRX), Entera Bio (ENTX), TScan Therapeutics (TCRX), IGM Biosciences (IGMS), Verrica Pharmaceuticals (VRCA), Cabaletta Bio (CABA), ESSA Pharma (EPIX), Zura Bio (ZURA), ImmunoPrecise Antibodies (IPA), and Quince Therapeutics (QNCX). These companies are all part of the "pharmaceutical products" industry. Finch Therapeutics Group vs. Its Competitors Forte Biosciences Entera Bio TScan Therapeutics IGM Biosciences Verrica Pharmaceuticals Cabaletta Bio ESSA Pharma Zura Bio ImmunoPrecise Antibodies Quince Therapeutics Finch Therapeutics Group (NASDAQ:FNCH) and Forte Biosciences (NASDAQ:FBRX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership. Is FNCH or FBRX more profitable? Finch Therapeutics Group's return on equity of -69.14% beat Forte Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Finch Therapeutics GroupN/A -69.14% -26.92% Forte Biosciences N/A -149.15%-114.25% Which has higher earnings and valuation, FNCH or FBRX? Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFinch Therapeutics GroupN/AN/A-$74.75M-$8.82-1.45Forte BiosciencesN/AN/A-$35.48M-$16.29-0.58 Which has more risk & volatility, FNCH or FBRX? Finch Therapeutics Group has a beta of 1.21, suggesting that its share price is 21% more volatile than the S&P 500. Comparatively, Forte Biosciences has a beta of 2.97, suggesting that its share price is 197% more volatile than the S&P 500. Do institutionals & insiders have more ownership in FNCH or FBRX? 21.8% of Finch Therapeutics Group shares are held by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are held by institutional investors. 44.9% of Finch Therapeutics Group shares are held by company insiders. Comparatively, 5.9% of Forte Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts prefer FNCH or FBRX? Forte Biosciences has a consensus target price of $61.00, suggesting a potential upside of 545.50%. Given Forte Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Forte Biosciences is more favorable than Finch Therapeutics Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Finch Therapeutics Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Forte Biosciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer FNCH or FBRX? In the previous week, Forte Biosciences had 2 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 3 mentions for Forte Biosciences and 1 mentions for Finch Therapeutics Group. Forte Biosciences' average media sentiment score of 1.29 beat Finch Therapeutics Group's score of 0.00 indicating that Forte Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Finch Therapeutics Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Forte Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryForte Biosciences beats Finch Therapeutics Group on 9 of the 13 factors compared between the two stocks. Get Finch Therapeutics Group News Delivered to You Automatically Sign up to receive the latest news and ratings for FNCH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FNCH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FNCH vs. The Competition Export to ExcelMetricFinch Therapeutics GroupBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$20.48M$276.97M$5.61B$9.30BDividend YieldN/AN/A4.23%4.03%P/E Ratio-1.45N/A28.5219.58Price / SalesN/A432.09426.1793.37Price / CashN/A22.4436.0257.93Price / Book0.899.478.135.54Net Income-$74.75M-$110.10M$3.24B$257.73M7 Day Performance-1.92%-0.96%0.20%-0.08%1 Month Performance-6.25%11.71%5.98%8.09%1 Year Performance706.96%17.13%26.15%13.02% Finch Therapeutics Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FNCHFinch Therapeutics Group0.7721 of 5 stars$12.75flatN/A+707.0%$20.48MN/A-1.45190Positive NewsFBRXForte Biosciences3.499 of 5 stars$12.48-1.3%$61.00+388.8%+42,163.0%$83.28MN/A-0.775Gap DownENTXEntera Bio2.5815 of 5 stars$1.78-2.7%$10.00+461.8%+0.5%$83.18M$180K-6.8520TCRXTScan Therapeutics3.5522 of 5 stars$1.70+17.2%$7.80+358.8%-75.1%$82.06M$2.82M-1.56100Gap UpIGMSIGM Biosciences4.6415 of 5 stars$1.33-1.5%$5.50+313.5%-87.0%$80.70M$2.68M-0.41190Positive NewsVRCAVerrica Pharmaceuticals4.4616 of 5 stars$0.86+3.8%$8.00+828.2%-90.5%$76.77M$7.57M-0.7240Gap UpCABACabaletta Bio2.7512 of 5 stars$1.51+1.3%$14.43+855.5%-79.1%$75.61MN/A-0.5950News CoverageEPIXESSA Pharma1.0674 of 5 stars$1.71+0.6%$2.00+17.0%-66.7%$75.46MN/A-2.7150ZURAZura Bio3.0839 of 5 stars$1.20+9.1%$14.33+1,094.4%-64.8%$75.21MN/A-1.713IPAImmunoPrecise Antibodies3.0027 of 5 stars$1.76+8.0%$4.00+127.3%+86.3%$74.60M$18.16M-1.5280Upcoming EarningsGap UpQNCXQuince Therapeutics3.0583 of 5 stars$1.61-1.2%$8.00+396.9%+130.7%$74.11MN/A-1.1660 Related Companies and Tools Related Companies FBRX Alternatives ENTX Alternatives TCRX Alternatives IGMS Alternatives VRCA Alternatives CABA Alternatives EPIX Alternatives ZURA Alternatives IPA Alternatives QNCX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FNCH) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Finch Therapeutics Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Finch Therapeutics Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FNCH Stock Alerts